Who has been buying Onconic Therapeutics stock?

4 distinct insiders have filed 8 disclosed insider purchases in Onconic Therapeutics (476060), most recently on 2026-07-02. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Onconic Therapeutics have?

Onconic Therapeutics has 8 buy-side and 13 sell-side disclosures on record, covering ₩17.9B ($12.4M) in total reported value, spanning 2024-12-19 to 2026-07-02.

Where does StockDrifts get Onconic Therapeutics insider data?

From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Onconic Therapeutics 476060

Company

온코닉테라퓨틱스Onconic Therapeutics

Insiders

Buys

Total Value

₩17.9B ($12.4M)

Avg Return

+100.96%

Last Filing

2026-07-02

Onconic Therapeutics (476060) has 8 disclosed insider purchases and 13 disclosed disposals on record, filed by 4 distinct insiders. Together those filings cover ₩17.9B ($12.4M) in reported transaction value. The earliest filing StockDrifts holds for Onconic Therapeutics is dated 2024-12-19; the most recent is 2026-07-02. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +100.96%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-07-02	SELL	Market Sell	김정훈 Kim Jeong-hoon	CEO	-20.0K	₩12,730	+0.7%	₩254M ($176K)
2026-07-01	SELL	Market Sell	김정훈 Kim Jeong-hoon	CEO	-87.7K	₩13,690	+7.7%	₩1.2B ($834K)
2026-06-29	SELL	Market Sell	김정훈 Kim Jeong-hoon	CEO	-12.3K	₩14,000	+9.7%	₩172M ($120K)
2026-06-26	SELL	Market Sell	김정훈 Kim Jeong-hoon	CEO	-81.0K	₩12,550	-0.7%	₩1.0B ($706K)
2026-06-05	SELL	Market Sell	김정훈 Kim Jeong-hoon	CEO	-28.6K	₩16,250	+0.2%	₩464M ($322K)
2026-04-28	SELL	Market Sell	차현주 Cha Hyun-joo	Managing Director	-20.0K	₩22,000	+8.4%	₩440M ($306K)
2026-04-13	BUY	신규선임	한상철 Sangcheol Han	president	22.8K	₩21,650	+0.7%	₩495M ($343K)
2026-04-10	BUY	주식매수청구권 행사	김진성 Jinseong Kim	Managing Director	72.0K	₩21,150	+3.1%	₩1.5B ($1.1M)
2026-04-10	BUY	주식매수청구권 행사	김정훈 Kim Jeong-hoon	CEO	140.0K	₩21,150	+3.1%	₩3.0B ($2.1M)
2026-04-10	BUY	주식매수청구권 행사	차현주 Cha Hyun-joo	Managing Director	90.0K	₩21,150	+3.1%	₩1.9B ($1.3M)
2026-04-10	BUY	주식매수청구권 행사	신종길 Shin Jong-gil	Managing Director	130.0K	₩21,150	+3.1%	₩2.7B ($1.9M)
2026-04-03	SELL	Market Sell	김진성 Jinseong Kim	Managing Director	-33.0K	₩20,300	-7.4%	₩670M ($465K)
2026-02-24	BUY	Market Buy	신종길 Shin Jong-gil	Managing Director	11.0K	₩25,450	-9.4%	₩281M ($195K)
2026-02-23	BUY	Market Buy	신종길 Shin Jong-gil	Managing Director	15.8K	₩19,580	+17.7%	₩309M ($215K)
2026-02-20	BUY	Market Buy	신종길 Shin Jong-gil	Managing Director	27.2K	₩18,890	+22.0%	₩514M ($357K)
2026-01-15	BUY	Market Buy	신종길 Shin Jong-gil	Managing Director	13.4K	₩19,160	+20.3%	₩256M ($178K)
2026-01-02	BUY	주식매수청구권 행사	신종길 Shin Jong-gil	Managing Director	132.0K	₩19,860	+16.1%	₩2.6B ($1.8M)
2026-01-02	BUY	주식매수청구권 행사	신종길 Shin Jong-gil	Managing Director	132.0K	₩19,860	+16.1%	₩2.6B ($1.8M)
2026-01-02	BUY	주식매수청구권 행사	김정훈 Kim Jeong-hoon	CEO	260.0K	₩19,860	+16.1%	₩5.2B ($3.6M)
2025-12-30	SELL	Market Sell	신종길 Shin Jong-gil	Managing Director	-218.0K	₩19,550	-17.9%	₩4.3B ($3.0M)
2025-12-30	SELL	Market Sell	신종길 Shin Jong-gil	Managing Director	-218.0K	₩19,550	-17.9%	₩4.3B ($3.0M)
2025-12-30	SELL	Market Sell	신종길 Shin Jong-gil	Managing Director	-12.5K	₩19,550	-17.9%	₩245M ($170K)
2025-12-30	SELL	Market Sell	김정훈 Kim Jeong-hoon	CEO	-120.0K	₩19,550	-17.9%	₩2.3B ($1.6M)
2025-12-30	SELL	Market Sell	신종길 Shin Jong-gil	Managing Director	-12.5K	₩19,550	-17.9%	₩245M ($170K)
2025-12-29	SELL	Market Sell	김정훈 Kim Jeong-hoon	CEO	-40.0K	₩22,350	-3.1%	₩894M ($621K)
2025-11-04	BUY	주식매수청구권 행사	김정훈 Kim Jeong-hoon	CEO	30.0K	₩14,870	+55.0%	₩446M ($310K)
2025-11-03	BUY	무상신주취득	제일약품 Jeil Pharmaceutical	-	15.8M	₩14,820	+55.5%	₩233.5B ($162.1M)
2025-10-28	BUY	주식매수청구권 행사	차현주 Cha Hyun-joo	Managing Director	5.2K	₩19,000	+21.3%	₩99M ($69K)
2025-10-28	BUY	주식매수청구권 행사	신종길 Shin Jong-gil	Managing Director	7.6K	₩19,000	+21.3%	₩145M ($101K)
2025-10-28	BUY	주식매수청구권 행사	차현주 Cha Hyun-joo	Managing Director	5.2K	₩19,000	+21.3%	₩99M ($69K)
2025-10-28	BUY	주식매수청구권 행사	신종길 Shin Jong-gil	Managing Director	7.6K	₩19,000	+21.3%	₩145M ($101K)
2025-10-13	BUY	무상신주취득	신종길 Shin Jong-gil	Managing Director	167.2K	₩21,750	+6.0%	₩3.6B ($2.5M)
2025-10-13	BUY	무상신주취득	김진성 Jinseong Kim	Managing Director	36.0K	₩21,750	+6.0%	₩783M ($544K)
2025-10-13	BUY	무상신주취득	김정훈 Kim Jeong-hoon	CEO	210.0K	₩21,750	+6.0%	₩4.6B ($3.2M)
2025-10-13	BUY	무상신주취득	차현주 Cha Hyun-joo	Managing Director	108.6K	₩21,750	+6.0%	₩2.4B ($1.6M)
2025-10-13	BUY	무상신주취득	제일약품 Jeil Pharmaceutical	-	15.0M	₩21,750	+6.0%	₩326.3B ($226.6M)
2025-10-13	BUY	무상신주취득	차현주 Cha Hyun-joo	Managing Director	128.7K	₩21,750	+6.0%	₩2.8B ($1.9M)
2025-10-13	BUY	무상신주취득	신종길 Shin Jong-gil	Managing Director	292.9K	₩21,750	+6.0%	₩6.4B ($4.4M)
2025-09-16	BUY	주식매수청구권 행사	신종길 Shin Jong-gil	Managing Director	4.5K	₩9,275	+148.5%	₩42M ($29K)
2025-09-16	BUY	주식매수청구권 행사	차현주 Cha Hyun-joo	Managing Director	8.7K	₩9,275	+148.5%	₩81M ($56K)
2025-09-16	BUY	주식매수청구권 행사	김정훈 Kim Jeong-hoon	CEO	20.0K	₩9,275	+148.5%	₩186M ($129K)
2025-09-16	BUY	주식매수청구권 행사	차현주 Cha Hyun-joo	Managing Director	8.7K	₩9,275	+148.5%	₩81M ($56K)
2025-09-16	BUY	주식매수청구권 행사	신종길 Shin Jong-gil	Managing Director	4.5K	₩9,275	+148.5%	₩42M ($29K)
2025-09-16	BUY	주식매수청구권 행사	김진성 Jinseong Kim	Managing Director	12.0K	₩9,275	+148.5%	₩111M ($77K)
2025-04-15	BUY	주식매수청구권 행사	차현주 Cha Hyun-joo	Managing Director	12.5K	₩6,062	+280.2%	₩76M ($53K)
2025-04-15	BUY	주식매수청구권 행사	신종길 Shin Jong-gil	Managing Director	18.1K	₩6,062	+280.2%	₩110M ($76K)
2025-04-15	BUY	주식매수선택권	김정훈 Kim Jeong-hoon	CEO	50.0K	₩6,062	+280.2%	₩303M ($210K)
2025-04-15	BUY	주식매수청구권 행사	차현주 Cha Hyun-joo	Managing Director	12.5K	₩6,062	+280.2%	₩76M ($53K)
2025-04-15	BUY	주식매수청구권 행사	신종길 Shin Jong-gil	Managing Director	18.1K	₩6,062	+280.2%	₩110M ($76K)
2025-03-14	BUY	주식매수청구권 행사	차현주 Cha Hyun-joo	Managing Director	15.0K	₩3,472	+563.9%	₩52M ($36K)

Showing the 50 most recent of 61 filings.

Frequently asked questions

Who has been buying Onconic Therapeutics stock?: 4 distinct insiders have filed 8 disclosed insider purchases in Onconic Therapeutics (476060), most recently on 2026-07-02. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Onconic Therapeutics have?: Onconic Therapeutics has 8 buy-side and 13 sell-side disclosures on record, covering ₩17.9B ($12.4M) in total reported value, spanning 2024-12-19 to 2026-07-02.
Where does StockDrifts get Onconic Therapeutics insider data?: From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Onconic Therapeutics. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.